NCT07661251Not yet recruiting
ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)
To Identify if Hair and Buccal Mucosa Samples Can Provide a Non-invasive, Practical, Accurate and Clinically Relevant Method to Determine the Internal Clock Time and to Monitor Individual Circadian Rhythms in Patients With Advanced Lung Cancer Receiving Immunotherapy-based Treatment.
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
Immunotherapy is a relatively new treatment that uses patients' own immune systems to fight diseases, particularly cancers. Recent studies suggest that the effectiveness of immunotherapy in cancer treatment may depend on the time of day it is given. This observational study wants to explore this further by looking at the effectiveness of immunotherapy in lung cancer patients in relation to their circadian rhythms. A circadian rhythm is the body's natural internal clock that regulates sleep, wakefulness, hormones, temperature and other bodily functions. They are roughly 24 hours long and respond to environmental cues, such as light and dark. An individual's circadian rhythm can be described by their chronotype which is their natural inclination to sleep at certain times of the day. Some people are 'early birds' or 'larks' and others are 'night owls'. It is usually difficult to determine a person's chronotype. A new tool has been developed by Warwick University called 'TimeTeller'. This study will see if TimeTeller can provide a non-invasive, practical, accurate and clinically relevant method to find out a person's chronotype by investigating specific genes in a single hair follicle or cheek swab sample. The study also aims to explore if different chronotypes respond better to immunotherapy treatments. Furthermore, it will look at whether immunotherapy changes the circadian rhythm. The results of this study may lead to further research in the future to explore how the timing of immunotherapy can work better for each individual. Additionally, it may provide greater insight into the impact immunotherapy has on human body clocks.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 23 Jan 2026
- Start date
- 15 Jun 2026
- Primary completion date
- Apr 2028
- Lead sponsor
- Laura Longshaw
- Diseases
- Lung cancer
- NCT number
- NCT07661251
What you commit to
- Study type: Observational
- Planned participants: 60
- From 15 Jun 2026 to the primary completion date, Apr 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- WHO PS \>2
- Uncontrolled comorbidities
- Lacking capacity
- Inability to wear biosensor bracelet
- Complete alopecia.
Who the study is looking for
- Histological diagnosis of NSCLC, stage IIIB-IV NSCLC, receiving pembrolizumab, atezolizumab and nivolumab (+/- chemotherapy) as, adjuvant, neoadjuvant or palliative treatment at Ysbyty Gwynedd
- WHO performance status (PS) \<2
- Full capacity
- No uncontrolled comorbidities
- Able to wear the biosensor bracelet
- Able to understand English
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.